These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36417351)

  • 21. An Electronic Clinical Decision Support System for the Assessment and Management of Suicidality in Primary Care: Protocol for a Mixed-Methods Study.
    Horrocks M; Michail M; Aubeeluck A; Wright N; Morriss R
    JMIR Res Protoc; 2018 Dec; 7(12):e11135. PubMed ID: 30530459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients.
    Kim K; Magness JW; Nelson R; Baron V; Brixner DI
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy.
    Brixner D; Biltaji E; Bress A; Unni S; Ye X; Mamiya T; Ashcraft K; Biskupiak J
    J Med Econ; 2016; 19(3):213-28. PubMed ID: 26478982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary Care Clinicians Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System.
    Olander M; Waring S; Stenehjem DD; Taran A; Ranelli P; Brown JT
    Innov Pharm; 2018; 9(2):1-12. PubMed ID: 34007697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services.
    Pasternak AL; Ward K; Irwin M; Okerberg C; Hayes D; Fritsche L; Zoellner S; Virzi J; Choe HM; Ellingrod V
    Clin Transl Sci; 2023 Feb; 16(2):292-304. PubMed ID: 36510710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.
    Chang WC; Tanoshima R; Ross CJD; Carleton BC
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():65-84. PubMed ID: 33006916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

  • 29. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.
    van Staa TP; Dyson L; McCann G; Padmanabhan S; Belatri R; Goldacre B; Cassell J; Pirmohamed M; Torgerson D; Ronaldson S; Adamson J; Taweel A; Delaney B; Mahmood S; Baracaia S; Round T; Fox R; Hunter T; Gulliford M; Smeeth L
    Health Technol Assess; 2014 Jul; 18(43):1-146. PubMed ID: 25011568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing a Clinical Decision Support Tool for Appropriate Antibiotic Prescribing in Australian General Practice: A Simulation Study.
    Manski-Nankervis JA; Biezen R; Thursky K; Boyle D; Clark M; Lo S; Buising K
    Med Decis Making; 2020 May; 40(4):428-437. PubMed ID: 32507028
    [No Abstract]   [Full Text] [Related]  

  • 31. General practitioners' accounts of negotiating antibiotic prescribing decisions with patients: a qualitative study on what influences antibiotic prescribing in low, medium and high prescribing practices.
    van der Zande MM; Dembinsky M; Aresi G; van Staa TP
    BMC Fam Pract; 2019 Dec; 20(1):172. PubMed ID: 31823739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
    Reizine NM; Danahey K; Truong TM; George D; House LK; Karrison TG; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Cancer; 2022 Apr; 128(8):1649-1657. PubMed ID: 35090043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics in primary care.
    Dawes M
    Healthc Manage Forum; 2020 May; 33(3):97-101. PubMed ID: 32054324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.
    Sung C; Lee PL; Tan LL; Toh DS
    Drug Saf; 2011 Dec; 34(12):1167-75. PubMed ID: 22077505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors affecting feasibility and acceptability of a practice-based educational intervention to support evidence-based prescribing: a qualitative study.
    Watkins C; Timm A; Gooberman-Hill R; Harvey I; Haines A; Donovan J
    Fam Pract; 2004 Dec; 21(6):661-9. PubMed ID: 15528289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
    Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
    Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving medication management for patients with multimorbidity in primary care: a qualitative feasibility study of the MY COMRADE implementation intervention.
    Sinnott C; Byrne M; Bradley CP
    Pilot Feasibility Stud; 2017; 3():14. PubMed ID: 28331631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample.
    Lunenburg CATC; Thirstrup JP; Bybjerg-Grauholm J; Bækvad-Hansen M; Hougaard DM; Nordentoft M; Werge T; Børglum AD; Mors O; Mortensen PB; Gasse C
    Transl Psychiatry; 2021 May; 11(1):294. PubMed ID: 34006849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
    Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
    Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
    Cheng CM; So TW; Bubp JL
    Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.